ArticleJournal of scleroderma and related disorders2026
Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes.
Article in Journal of scleroderma and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore variations in disease presentation between isolated systemic sclerosis (SSc), primary biliary cholangitis (PBC) and SSc-PBC overlap syndrome. Design: Systematic review conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Setting: Literature search of PubMed, Scopus and Google Scholar for studies published through June 2025. Participants: 13 studies (from 1331 initially identified records) including patients with isolated SSc, isolated PBC and SSc-PBC overlap were included. Eligible studies were case-control or cohort designs reporting demographic, serological or clinical outcomes. Interventions: Not applicable. Main outcome measures: Differences in clinical phenotype, serological markers, systemic involvement and mortality between SSc-PBC overlap and isolated disease groups. Results: Patients with SSc-PBC overlap demonstrated distinct clinical characteristics compared with isolated disease phenotypes. Anticentromere antibody and antimitochondrial antibody positivity were significantly higher in overlap patients. The overlap group predominantly included patients with limited cutaneous SSc and had a higher prevalence of extrahepatic autoimmune diseases, particularly Sjögren's syndrome and Hashimoto's thyroiditis. Systemic involvement, including pulmonary, musculoskeletal and cardiac manifestations, was less pronounced in overlap patients compared with isolated SSc. Liver-related mortality was higher in the PBC-only group, whereas mortality in the overlap group was primarily attributable to SSc-related causes. Conclusions: SSc-PBC overlap syndrome represents a distinct clinical and immunological entity. Recognition of this phenotype may facilitate earlier diagnosis, guide management strategies and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.